A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland

Serum and urinary prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) from 20 dogs were measured. PAP and PSA tests were carried out in authomatized equipment with commercial kits used for humans. Mean PAP serum value was 0.7U/l and urinary 0.1U/l. Mean serum and urinary PSA were 0.005ng/dl and 0.004ng/dl, respectively. In vivo determination of these two biomarkers in dogs is a new form of diagnosis in veterinary medicine and these values should be correlated with the morphological lesion of the prostate gland.

Download Full-text

Clinical Behaviour of Prostatic Specific Antigen and Prostatic Acid Phosphatase: A Comparative Study

The International Journal of Biological Markers ◽

10.1177/172460088900400205 ◽

1989 ◽

Vol 4 (2) ◽

pp. 87-94 ◽

Cited By ~ 7

Author(s):

J. Morote Robles ◽

A. Ruibal Morell ◽

J.A. De Torres Mateos ◽

A. Soler Roselló

Keyword(s):

Acid Phosphatase ◽

False Positive ◽

Normal Limit ◽

Specific Antigen ◽

Benign Prostatic Hypertrophy ◽

Prostatic Acid Phosphatase ◽

Serum Levels ◽

Prostatic Hypertrophy ◽

Prostatic Specific Antigen ◽

Positive Results

We assayed prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels in 1383 patients using a double antibody radioimmunoassay (RIA) I125. Establishing the upper normal limit in 10 ng/ml PSA and 2.5 ng/ml for PAP, the false positive results were only 1.9 and 5.1 percent in men with non-prostatic benign or malignant pathology and respectively 0 and 2.2 percent in women. We detected false positive levels for these two tumoral markers in 3.5 and 4.7 percent of patients with non-complicated benign prostatic hypertrophy, 64.8 and 19.2 percent in complicated benign prostatic hypertrophy, 24 and 16 percent in acute prostatitis and 3.3 percent in chronic prostatitis. The sensitivity in patients with prostate cancer was 87.2 percent for PSA and 64.1 percent for PAP, and there was a better correlation with PSA than PAP for tumoral spread and histological grading. Finally, clinical efficacy was higher with PSA and was no better when both markers were assayed.

Download Full-text

The Ultrastructural Localization of Prostatic Specific Antigen and Prostatic Acid Phosphatase in Hyperplastic and Neoplastic Human Prostates

The Journal of Urology ◽

10.1016/s0022-5347(17)47311-3 ◽

1985 ◽

Vol 134 (3) ◽

pp. 607-613 ◽

Cited By ~ 29

Author(s):

Michael J. Warhol ◽

Janina A. Longtine

Keyword(s):

Acid Phosphatase ◽

Specific Antigen ◽

Prostatic Acid Phosphatase ◽

Ultrastructural Localization ◽

Prostatic Specific Antigen

Download Full-text

Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.

Clinical Chemistry ◽

10.1093/clinchem/32.11.2040 ◽

1986 ◽

Vol 32 (11) ◽

pp. 2040-2043 ◽

Cited By ~ 30

Author(s):

J K Siddall ◽

S D Shetty ◽

E H Cooper

Keyword(s):

Acid Phosphatase ◽

Disease Progression ◽

Prostate Specific Antigen ◽

Prostatic Cancer ◽

Specific Antigen ◽

Prostatic Acid Phosphatase ◽

Carcinoma Of The Prostate ◽

Normal Limits ◽

Bony Metastases

Abstract We have compared the concentrations in serum of gamma-seminoprotein (gamma-SM) and prostate specific antigen (PSA), two antigens of prostatic origin that are synthesized independently of prostatic acid phosphatase (PAP, EC 3.1.3.2), to assess their potential in monitoring prostatic cancer. At presentation, 27/30 (90%) patients with metastases had a PSA concentration greater than 10 ng/mL, and 29/30 (97%) a gamma-SM concentration greater than 10 ng/mL; 21/61 (34%) with disease but without metastases had an abnormal content of PSA, and 23/61 (38%) an abnormal gamma-SM. Concentrations of PSA and gamma-SM were significantly correlated (r = 0.68, p less than 0.001). In 20 patients without metastases followed longitudinally, the median concentrations of gamma-SM, PSA, and PAP in the 13 patients who developed bony metastases or showed signs of local spreading of the tumor were 58 ng/mL, 34 ng/mL, and 2.1 U/L, respectively. The corresponding median values in the seven patients who remained clinically stable were 2.5 and 3.9 ng/mL, and 2.3 U/L. We conclude that either PSA or gamma-SM can warn of disease progression when PAP activities are still within normal limits.

Download Full-text